Editas Medicine Inc (EDIT) - Total Liabilities
Based on the latest financial reports, Editas Medicine Inc (EDIT) has total liabilities worth $132.08 Million USD as of June 2026. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Explore Editas Medicine Inc (EDIT) long-term investment share to see how much of total assets are deployed in long-term investments.
Editas Medicine Inc - Total Liabilities Trend (2013–2025)
This chart illustrates how Editas Medicine Inc's total liabilities have evolved over time, based on quarterly financial data. For the complete balance sheet picture, see total assets of Editas Medicine Inc.
Editas Medicine Inc Competitors by Total Liabilities
The table below lists competitors of Editas Medicine Inc ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Hualan Group Co Ltd
SHE:301027
|
China | CN¥1.13 Billion |
|
Nanjing Textiles Import & Export Corp Ltd
SHG:600250
|
China | CN¥967.20 Million |
|
HCM II Acquisition Corp
NASDAQ:HOND
|
USA | $15.00 Million |
|
Hangzhou Everfine Photo E Info
SHE:300306
|
China | CN¥81.67 Million |
|
Atea Pharmaceuticals Inc
NASDAQ:AVIR
|
USA | $28.12 Million |
|
Studio Dragon Corporation
KQ:253450
|
Korea | ₩234.22 Billion |
|
Shenzhen Glory Medical Co Ltd
SHE:002551
|
China | CN¥631.49 Million |
|
Chongqing Sansheng Building Materials Co Ltd
SHE:002742
|
China | CN¥895.14 Million |
Liability Composition Analysis (2013–2025)
This chart breaks down Editas Medicine Inc's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. See EDIT equity to assets ratio to measure how much of total assets are equity-financed.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 3.19 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 1.25 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.56 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Editas Medicine Inc's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Editas Medicine Inc (2013–2025)
The table below shows the annual total liabilities of Editas Medicine Inc from 2013 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-12-31 | $159.25 Million | -23.19% |
| 2024-12-31 | $207.31 Million | +38.16% |
| 2023-12-31 | $150.06 Million | -2.33% |
| 2022-12-31 | $153.64 Million | +24.06% |
| 2021-12-31 | $123.84 Million | -30.82% |
| 2020-12-31 | $179.02 Million | -27.36% |
| 2019-12-31 | $246.45 Million | +33.78% |
| 2018-12-31 | $184.22 Million | +11.53% |
| 2017-12-31 | $165.18 Million | +74.66% |
| 2016-12-31 | $94.58 Million | -59.32% |
| 2015-12-31 | $232.48 Million | +745.99% |
| 2014-12-31 | $27.48 Million | +547.50% |
| 2013-12-31 | $4.24 Million | -- |
About Editas Medicine Inc
Editas Medicine, Inc., a clinical stage genome editing company, focuses on developing transformative genomic medicines to treat a range of serious diseases. The company develops a proprietary gene editing platform based on CRISPR technology. Its lead program is EDIT-401, a one-time therapy designed to reduce LDL cholesterol through the upregulation of the LDL receptor to treat hyperlipidemia. The… Read more